A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy

Abstract Background To assess the efficacy and safety of a combination therapy involving fimasartan, amlodipine, and rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond to fimasartan monotherapy. Methods This phase III, randomized, double-blind, multicenter stud...

Descrición completa

Detalles Bibliográficos

Principais autores:	Eun-Seok Jeon, Sang Wook Lim, Seok-Yeon Kim, Hyoung-Mo Yang, Moo Hyun Kim, Moo-Yong Rhee, Seung Hwan Han, Jinho Shin, Kwang-il Kim, Jin-Ok Jeong, Ki Chul Sung, Geu Ru Hong, Hyung-Seop Kim, Kihwan Kwon, Tae-Soo Kang, Hae-Young Lee, Su-Eun Han
Formato:	Artigo
Idioma:	Inglês
Publicado:	XMLink 2022-12-01
Series:	Clinical Hypertension
Assuntos:	Hypertension Dyslipidemias Fimasartan Amlodipine Rosuvastatin Combination drug therapy
Acceso en liña:	https://doi.org/10.1186/s40885-022-00223-4
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!